Notice of AGM

Oxford Biomedica PLC
29 March 2007







For Immediate Release                                           29 MARCH 2007


               OXFORD BIOMEDICA: NOTICE OF ANNUAL GENERAL MEETING

Oxford, UK - 29 March 2007: Oxford BioMedica (LSE: OXB), the leading gene
therapy company, announces today that it will be holding its Annual General
Meeting on Thursday, 3 May 2007, 11.00am, at the offices of Morrison & Foerster
MNP, CityPoint, One Ropemaker Street, London EC2Y 9AW. A notice of the 2007
Annual General Meeting will be sent to shareholders on 2 April 2007.

                                        
                                     -Ends-



For further information, please contact:
Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive            Tel: [phone]
City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson        Tel: [phone]
Buchanan Communications
Scientific/Trade Press Enquiries:

Gemma Price/ Holly Griffiths/ Katja Stout           Tel: [phone]

Northbank Communications


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on oncology and
neurotherapy. The Company was established in 1995 as a spin out from Oxford
University, and is listed on the London Stock Exchange.


Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes TroVax(R), a cancer immunotherapy, which was recently licensed to
Sanofi-Aventis for global development and commercialisation. TroVax is in Phase
III development for renal cancer and Sanofi-Aventis is implementing a
development plan for metastatic colorectal cancer. The recent acquisition of
Oxxon Therapeutics adds a Phase II cancer immunotherapy for melanoma, HI-8 MEL
(R), to the Company's pipeline. Other oncology product candidates include a gene
therapy, MetXia(R), which is in Phase II development for pancreatic cancer, and
a preclinical targeted antibody therapy, which is being developed in
collaboration with Wyeth. In neurotherapy, the Company's lead product, ProSavin,
is expected to enter clinical trials in Parkinson's disease in 2007. The
preclinical pipeline includes gene-based products for vision loss, motor neuron
disease and nerve repair. The acquisition Oxxon also provides a platform for the
development of therapeutic vaccines for infectious diseases.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 75 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. In addition to the
TroVax collaboration with Sanofi-Aventis and the targeted antibody therapy
collaboration with Wyeth, Oxford BioMedica has corporate collaborations with
Intervet, Sigma-Aldrich, Viragen, MolMed and Virxsys; and has licensed
technology to a number of companies including Merck & Co, Biogen Idec,
GlaxoSmithKline and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange